在严重的COVID-19中使用托西利祖马布 - 一个随机,双盲,安慰剂控制的试验
Muhammad Irfan Malik1,2,3, Sardar Al Fareed Zafar1,2,3, Fabiha Qayyum2,3
1Postgraduate Medical Institute, Lahore, Pakistan.
托西利祖马布 (tocilizumab) 是一种联素-6受体抑制剂,在治疗重症COVID-19患者方面表现有前途. 这种药物降低了死亡率,改善了炎症标志物,并在严重病例中缩短了住院时间.
科学领域:
- 关键护理医学 关键护理医学
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 对于重症COVID-19患者,干白素-6受体抑制剂的有效性仍然不确定.
- 严重的急性呼吸系统综合征-冠状病毒-2 (SARS-CoV-2) 感染可能导致需要密集护理的严重疾病.
研究的目的:
- 评估托西利祖马布在患有COVID-19的重症成人患者中的疗效和安全性.
- 评估托西利祖马布对康复或死亡的影响作为主要结果.
主要方法:
- 进行了一项随机,双盲,安慰剂控制的第二阶段试验.
- 患者接受了标准的医疗治疗加上托西利祖马布或安慰剂,比例为4:1.
- 主要结局是死亡率或康复;次要结局包括临床康复,症状恶化和出院.
主要成果:
- 该研究包括190名患者 (152名托西利祖马布,38名安慰剂).
- 与安慰剂 (15.6天) 相比,托西利祖马布组的住院时间较短 (12.9天).
- 托西利祖马布组的死亡率为17.8%,而安慰剂组的死亡率为76.3%,16日炎症标志物显著改善.
结论:
- 托西利祖马布的使用与严重COVID-19的死亡率降低有关.
- 该药物早些时候在炎症标志物中表现出改善.
- 托西利祖马布与重症COVID-19患者的住院时间缩短有关.
更多相关视频
04:59Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
